Clinical Trials Logo

Nervous System Diseases clinical trials

View clinical trials related to Nervous System Diseases.

Filter by:

NCT ID: NCT03325374 Completed - Clinical trials for Functional Neurological Disorder

BLB Study Back or Leg Pain and Bladder Symptoms Study

BLB
Start date: November 2015
Phase:
Study type: Observational

The research focuses on Cauda Equina Syndrome (CES) which describes damage to the nerves in the lower back which supply bladder, bowels, sexual function and the legs usually from slipped discs in the spine. CES is as common as multiple sclerosis and is diagnosed using an MRI scan of the spine, 'scan positive' CES. However, about 50% of people presenting with the symptoms of CES have MRI scans which do not explain their symptoms, 'scan negative' patients. The BLB study will be the first large clinical study comparing patients with 'scan positive' and 'scan negative' CES. All patients admitted to the Western General Hospital, Edinburgh with possible CES will be invited to participate. The study consists of detailed history taking, examination and a questionnaire following up patient's symptoms at three months. The study aims to see what differences exist between the 'scan positive' and 'scan negative' groups, help doctors understand more about the outcomes of both groups and discover the number of patients with 'scan negative' CES who have functional disorders (previously called medically unexplained or conversion disorders) or undiagnosed neurological disorders.

NCT ID: NCT03322904 Completed - Clinical trials for Autonomic Nervous System Diseases

Sympathetic-parasympathetic Ratio of Our Gaze

Start date: March 10, 2016
Phase: N/A
Study type: Observational

ABSTRACT BACKGROUND The existence of the retinohypothalamic pathway suggests that light may influence autonomic outflow activity. The objective of this study was to examine the correlation between the estimated iris muscle sympathetic‒parasympathetic area (IRIS) ratio and the sympathetic-parasympathetic ratio (low frequency [LF]/high frequency [HF] ratio). METHODS The study population consisted of 200 females and 200 males (mean age, 32.4 ± 7.1 years). The IRIS ratio was determined from digital photographs of the iris in a computer setting. The LF/HF ratio was determined from records of heart rate variability obtained using a Holter implementation.

NCT ID: NCT03320798 Completed - Bullous Pemphigoid Clinical Trials

Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients

Start date: October 1, 2013
Phase: N/A
Study type: Observational

Bullous pemphigoid affects mainly elderly patients. It is often associated with neurologic disorders, which represent a major risk factor of the disease

NCT ID: NCT03314610 Completed - Clinical trials for Lower Urinary Tract Symptoms

Effect of Need to Void on Parkinsonian Gait

Start date: October 16, 2017
Phase:
Study type: Observational

This study evaluates the effect of the need to void on parkinsonian gait

NCT ID: NCT03300986 Completed - Clinical trials for Gait Disorders, Neurologic

Parameter Changes in Functional Electrical Stimulation

Start date: April 1, 2016
Phase: N/A
Study type: Observational

This study aims to look at how changes to a person's functional electrical stimulation might change how they walk. Functional electrical stimulation (FES) is commonly used to help people with foot drop from upper motor neurone conditions such as stroke or multiple sclerosis. This group of people have muscle weakness which makes it difficult to lift the foot, which causes trips and falls. FES reduces foot drop by using a portable device to apply short electrical pulses to the nerve which lifts the foot. The FES device stimulates this nerve only during the swing phase, when the foot is off the floor. Typically this is achieved by using a foot-switch, which detects when the heel leaves the floor. Stimulation begins a short interval of time after the heel leaves the floor, ramps up from zero to set stimulation for the individual, and at another period of time after the heel hits the floor, stimulation ramps down from set amount to zero. There are four time intervals described here which can be varied by the clinician on the device:- - Delay (the time between heel lift and the start of stimulation) - Ramp up (the time for stimulation to reach full strength) - Extension (the time between heel strike and the ramp down) - Ramp down (the time for stimulation to reach zero from full strength) These intervals are usually set by experienced clinicians using a qualitative assessment of the patient's walking and trial-and-error. A literature review has found no published studies which compare walking with different timing. This knowledge would be useful for clinicians, who could use this information as a starting point in finding the best timing parameters for each patient.

NCT ID: NCT03300856 Completed - Clinical trials for Neurological Disorder

Chart Review: Central Motor Conduction Time in Neurological Disorders

Start date: October 4, 2017
Phase:
Study type: Observational

Background: TMS stands for transcranial magnetic stimulation. It is a non-invasive way to stimulate the brain. It helps researchers study the nervous system. TMS can assess central motor conduction time (CMCT). That can be used to diagnose some diseases. It can also show how well treatments are working. Researchers want to study the records of people who have already had TMS. They want to see how it relates to the results of diagnostic studies. Objectives: To study the results of transcranial magnetic stimulation in certain neurological disorders. To create a descriptive analysis of the results. Eligibility: Records that are already in the NINDS database Design: The study will not enroll any participants. Researchers will search the database for certain terms. These include TMS, CMTC, and motor evoked potentials. This will identify records of people who had TMS for diagnosis. Using data from the records, researchers will calculate CMCT. They will note other data that relate to CMCT. Researchers will analyze their findings. They will write a review article. Personal data will be removed from all the records before the findings are analyzed.

NCT ID: NCT03295786 Completed - Parkinson Disease Clinical Trials

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease

Start date: September 26, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the safety and tolerability of CDNF in patients with Parkinson's disease, when dosed directly into the brain using an implanted investigational drug delivery system (DDS). Safety and accuracy of the DDS is also being evaluated. One-third of the patients will receive monthly infusions with placebo and two-third of the patients will receive monthly infusions with either mid- or high-doses of CDNF for a period of 6 months.

NCT ID: NCT03292848 Completed - ADHD Clinical Trials

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

Start date: October 10, 2017
Phase: Phase 1
Study type: Interventional

A study to assess pharmacokinetics, safety and tolerability of brexpiprazole in children ages 6 to <13 years with CNS disorders.

NCT ID: NCT03264235 Completed - Stroke, Acute Clinical Trials

The Effect of Powered-Knee Exoskeleton Assist on Stair Climbing in Acute CVA

Start date: August 30, 2017
Phase: N/A
Study type: Interventional

Hypothesis/Specific Aims: The purpose of this research study is to determine if using an exoskeleton during stair climbing training will result in an improved ability to walk and climb stairs in individuals affected by recent stroke as compared to stair climbing training without an exoskeleton.

NCT ID: NCT03250988 Completed - Clinical trials for Nervous System Diseases

Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long-Term Care Facility

Start date: January 30, 2018
Phase:
Study type: Observational

The purpose of this study is to improve spasticity diagnosis through exploration of potential new diagnostic markers for spasticity that can assist in diagnosis and referral.